Search Results

BioSkryb Genomics announced a partnership with Research Instruments Pte Ltd, a premier distributor for genomic and life science research products in Southeast Asia, to distribute BioSkryb’s ResolveDNA® and ResolveOME™ single cell amplification tools throughout Singapore and Southeast Asia.

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems, and Radiant Digital PTE Ltd. a provider of digital transformation delivery services to commercial and government clients, have partnered to facilitate the digital transformation of life sciences companies in Singapore.

Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced promising safety and efficacy data from a study of its off-the-shelf CD30.CAR EBVST therapy in patients with relapsed or refractory Hodgkin lymphoma.

Tessa Therapeutics Ltd. announced entry into a Cooperative Research and Development Agreement with the U.S. National Cancer Institute, part of the National Institutes of Health, to investigate TT11X, Tessa’s allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy, in multiple subtypes of non-Hodgkin lymphoma.

Tessa Therapeutics Ltd. announced two presentations featuring clinical data from the company’s autologous CD30.CAR-T therapy TT11 and off-the-shelf CD30 CAR EBVST therapy will be featured at the 17th International Conference on Malignant Lymphoma taking place from June 13-17, 2023, at Lugano, Switzerland.

SCG Cell Therapy Pte Ltd announced that U.S. Food and Drug Administration has approved the Investigational New Drug application to initiate Phase 1/2 clinical trial for SCG142, a novel next-generation human papillomavirus E7-specific T-cell receptor-engineered T cell therapy for patients with HPV-associated solid tumors.

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.

Hyphens Pharma International Limited is pleased to announce that its subsidiary, Hyphens Pharma Pte. Ltd., has entered into an exclusive license, supply and commercialisation agreement with MC2 Therapeutics for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.

Tessa Therapeutics Ltd. announced that the company will prioritize development of its allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy platform, while seeking strategic options for the development of its TT11 autologous CAR-T platform with other companies.